Reuters logo
3 months ago
BRIEF-Xoma announces positive results from its phase 2 study of prolactin inhibition
April 24, 2017 / 11:14 AM / 3 months ago

BRIEF-Xoma announces positive results from its phase 2 study of prolactin inhibition

1 Min Read

April 24 (Reuters) - Xoma Corp

* Xoma announces positive results from its phase 2 proof-of-concept study of prolactin inhibition

* Xoma Corp says has achieved positive phase 2 proof-of-concept results for x213 in physiological hyperprolactinemia

* Xoma Corp - while study was not intended, or powered to show statistical significance, it demonstrated that X213 was safe and well tolerated Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below